Department of Health and Social Care written question – answered on 30th September 2019.

Alert me about debates like this

Photo of Seema Malhotra Seema Malhotra Labour/Co-operative, Feltham and Heston

To ask the Secretary of State for Health and Social Care, what recent assessment he has had made of the effectiveness of Maraviroc in patients with progressive multifocal leukoencephalopathy (PML).

Photo of Nadine Dorries Nadine Dorries The Parliamentary Under-Secretary for Health and Social Care

Maraviroc (brand name Celsentri) is currently authorised through the European centralised procedure for the treatment of patients who are infected with HIV type 1. It is used in combination other HIV medicines.

The Medicines and Healthcare products Regulatory Agency which is responsible for the regulation of medicines in the United Kingdom is not aware of any application for maraviroc for use in patients with progressive multifocal leukoencephalopathy (PML) and cannot therefore comment on the efficacy of this drug in patients with PML.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.